01 10Alimta
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 2,330
2019 Revenue in Millions : 2,116
Growth (%) : 10
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 2,061
2020 Revenue in Millions : 2,330
Growth (%) : -12
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 928
2021 Revenue in Millions : 2,061
Growth (%) : -55
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 218
2022 Revenue in Millions : 928
Growth (%) : -77
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 2,792
2014 Revenue in Millions : 2,493
Growth (%) : -11%
Main Therapeutic Indication : Oncology
Currency : USD
2014 Revenue in Millions : 3.30%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 2,283
2015 Revenue in Millions : 2,493
Growth (%) : -8
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 2,063
2016 Revenue in Millions : 2,283
Growth (%) : -10
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 2,133
2017 Revenue in Millions : 2,063
Growth (%) : 3%
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 2,116
2018 Revenue in Millions : 2,133
Growth (%) : -1
LOOKING FOR A SUPPLIER?
